Industrial Synthesis Route and Impurity Control for 3-Ethynylimidazo[1,2-b]pyridazine

• [Reaction Kinetics]: Optimized non-palladium catalytic pathways ensure consistent yields exceeding 78% across multi-step sequences.
• [Procurement Logic]: Secure tonnage quantities with factory-direct pricing models that mitigate spot-market volatility.
• [Compliance Framework]: Manufactured under strict GMP guidelines to meet global regulatory standards for kinase inhibitor precursors.

The demand for high-purity heterocyclic building blocks continues to surge within the oncology sector, specifically for the production of third-generation tyrosine kinase inhibitors. 3-Ethynylimidazo[1,2-b]pyridazine (CAS: 943320-61-4) serves as a critical pharmaceutical intermediate in the synthesis of Ponatinib, a drug utilized for treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. For process chemists and procurement officers, understanding the nuances of the synthesis route and impurity profiles is essential for ensuring batch-to-batch consistency and commercial viability.

Optimizing Reaction Yields for Imidazo[1,2-b]pyridazine Core

Traditional synthetic methodologies often rely on Heck reaction processes involving noble metal palladium catalysts and expensive reagents like trimethylsilyl acetylene. While effective on a laboratory scale, these routes present significant challenges for industrial scaling, including high production costs and the difficulty of removing trace metal impurities. Modern manufacturing process optimizations have shifted towards active ester methods that bypass these bottlenecks.

An optimized industrial route typically initiates with the condensation of 3-pyridazinone and 2-chloroethylamine hydrochloride under alkaline conditions. This step avoids the use of toxic 2-chloroacetaldehyde, enhancing workplace safety and environmental compliance. Subsequent bromination using N-bromosuccinimide (NBS) followed by esterification with sodium p-toluenesulfonate creates an active intermediate. The final step involves the introduction of acetylene gas in an aprotic solvent under pressure. This sequence has demonstrated step yields of approximately 89%, 80%, and 79% respectively, resulting in a robust overall process suitable for large-scale production. When sourcing high-purity 3-Ethynylimidazo[1,2-b]pyridazine, buyers should verify that the supplier utilizes such cost-effective, metal-free catalytic systems to ensure lower impurity loads.

Managing Impurity Profiles in Kinase Inhibitor Precursor

For R&D teams, the impurity profile of this kinase inhibitor precursor is paramount. Common impurities include unreacted brominated intermediates, over-alkylated byproducts, and residual solvents such as DMF or DMSO. Achieving industrial purity requires rigorous purification steps, often involving suction filtration, water precipitation, and controlled drying processes.

Quality control protocols must account for the specific physical properties of the compound, which typically presents as a white to grey solid with a molecular weight of 143.15 g/mol. Storage conditions are equally critical; the material should be maintained at 2-8°C to prevent degradation of the ethynyl group. Advanced analytical methods, including HPLC and NMR, are employed to confirm the absence of genotoxic impurities and ensure the material meets the stringent requirements for downstream coupling reactions.

Technical Specifications and Quality Parameters

To facilitate quick evaluation for procurement and quality assurance teams, the following table outlines the standard technical specifications for commercial-grade material.

Parameter	Specification	Test Method
CAS Number	943320-61-4	Verified
Molecular Formula	C8H5N3	Elemental Analysis
Molecular Weight	143.15 g/mol	MS
Purity (HPLC)	≥ 98.0% (Commercial Grade)	Area Normalization
Appearance	White to Grey Solid	Visual Inspection
Storage Temperature	2-8°C	Stability Study
Packing Size	1kg to 25kg (Customizable)	Inventory

Supply Chain Stability and Global Manufacturing

Executives and procurement managers must prioritize supply chain resilience. Market data indicates significant price fluctuations for small-quantity research packs, but bulk procurement strategies stabilize costs for commercial production. As a global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. focuses on providing scalable solutions that align with long-term production schedules. We maintain substantial inventory levels to support custom synthesis requests and ensure timely delivery for clinical and commercial phases.

Reliable supply involves more than just availability; it requires comprehensive documentation. Every batch is accompanied by a Certificate of Analysis (COA) and Safety Data Sheet (SDS), ensuring full traceability and regulatory compliance. This level of transparency is crucial for audit readiness and maintaining the integrity of the final drug product.

Conclusion

The efficient production of Ponatinib intermediates relies on optimized synthetic routes that balance yield, safety, and cost. By adopting metal-free catalytic methods and adhering to strict impurity controls, manufacturers can deliver high-quality organic building block materials suitable for complex drug synthesis. For partners seeking a reliable supply chain partner, NINGBO INNO PHARMCHEM CO.,LTD. stands ready to support your development goals with premium materials and technical expertise.

To proceed with your project, please contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote.